Asset Details
Do you wish to reserve the book?
Lutatherasup.® Orphans: State of the Art and Future Application of Radioligand Therapy with sup.177Lu-DOTATATE
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lutatherasup.® Orphans: State of the Art and Future Application of Radioligand Therapy with sup.177Lu-DOTATATE
Do you wish to request the book?
Lutatherasup.® Orphans: State of the Art and Future Application of Radioligand Therapy with sup.177Lu-DOTATATE
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lutatherasup.® Orphans: State of the Art and Future Application of Radioligand Therapy with sup.177Lu-DOTATATE
2023
Overview
Lutathera[sup.®] is the first EMA- and FDA-approved radiopharmaceutical for radioligand therapy (RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive unresectable somatostatin receptor (SSTR) positive gastroenteropancreatic (GEP) neuroendocrine neoplasms (NET) can be treated with Lutathera[sup.®] . Conversely, patients with SSTR-positive disease arising from outside the gastroenteric region do not currently have access to Lutathera[sup.®] treatment despite several papers in the literature reporting the effectiveness and safety of RLT in these settings. Moreover, patients with well-differentiated G3 GEP-NET are also still “Lutathera orphans”, and retreatment with RLT in patients with disease relapse is currently not approved. The aim of this critical review is to summarize current literature evidence assessing the role of Lutathera[sup.®] outside the approved indications. Moreover, ongoing clinical trials evaluating new possible applications of Lutathera[sup.®] will be considered and discussed to provide an updated picture of future investigations.
Publisher
MDPI AG
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.